Workshop on Building a Renal Denervation Program-Two New Documents to Review: AHA Scientific Statement, ESC Guidelines, Dr. Katherine J. Kunkel

Two New Documents to Review: AHA Scientific Statement, ESC Guidelines, Dr. Katherine J. Kunkel

Video Transcription

Video Summary

The presentation discusses renal denervation (RDN) as a treatment for hypertension, exploring its efficacy, safety, and patient selection process. RDN targets overactive sympathetic nervous systems, using Medtronic Simplicity Spiral RDN and ReCore Medical Paradise systems to ablate renal artery nerves, reducing blood pressure. Data shows significant and durable blood pressure reduction with both radiofrequency and ultrasound methods, often comparable to a single antihypertensive drug's effect. The AHA emphasizes patient selection, focusing on true resistant hypertension and those with medication intolerance. Despite promising results, the ESC highlights concerns such as modest effect size, cost-effectiveness, and lack of cardiovascular outcomes trials. Guidelines suggest targeting uncontrolled hypertension cases only, confirming primary hypertension, and assessing cardiovascular risk. The patient’s role in decision-making is crucial, as their interest and consent significantly influence treatment choice. Overall, RDN's safety and efficacy support its growing use and future guideline development.

Keywords

renal denervation

hypertension treatment

sympathetic nervous system

blood pressure reduction

patient selection